INOVIQ TO PRESENT NEW EXO-NET DATA AT ISEV ANNUAL MEETING

- **INOVIQ to present new EXO-NET® data at the International Society for Extracellular Vesicles (ISEV) Annual Meeting 2023 in Seattle, USA**
- **The new data further supports application of INOVIQ's EXO-NET technology in the isolation of exosome-based biomarkers for use in development of earlier and more accurate diagnostic tests for Oncology and other diseases**
- **The new data will be released at the start of the ISEV meeting, being held May 17-21, 2023**

Melbourne, Australia, 19 April 2023: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) will present new data further confirming the effectiveness of its proprietary exosome isolation technology, EXO-NET®, at the upcoming Annual Meeting of the International Society for Extracellular Vesicles (ISEV) in Seattle, USA from May 17-21, 2023.

INOVIQ CEO, Dr Leearne Hinch said: *"The presentations highlight the use of EXO-NET for fast and efficient exosome isolation, biomarker discovery, and the development of transformative exosome-based diagnostics for cancer, neurological and other diseases. ISEV's Annual Meeting is the leading global exosome scientific conference for INOVIQ to showcase these important advances to key opinion leaders in the extracellular vesicle field worldwide.*

INOVIQ's next-generation EXO-Ovarian Cancer Test is being developed using EXO-NET to isolate exosomes from a simple blood sample and hopes to provide a life-saving blood test to detect ovarian cancer early when it can be cured."

INOVIQ and its collaborators, including the University of Queensland and Johns Hopkins University, will present four poster and one oral presentation at ISEV2023. The presentations cover:

- Research completed by Associate Professor Kenneth Witwer's team at Johns Hopkins University clearly establishes the benefits of using EXO-NET for isolating and enriching exosomes to identify biomarkers using mass spectrometry.
- Data from Associate Professor Carlos Salomon's team from the Translational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group at The University of Queensland further highlight the suitability of EXO-NET for developing new multi-marker tests for ovarian cancer. The team used mass spectrometry and next generation sequencing to identify the presence of EXO-NET isolated biomarkers in the blood of women with early-stage ovarian cancer. These biomarkers were combined in an algorithm to more accurately identify women with early-stage ovarian cancer.
- INOVIQ will report the results of an extensive analytical validation of EXO-NET for isolating exosomes from plasma, saliva and cell-conditioned medium and the downstream analysis of exosomal microRNA, messenger RNA and proteins.
- INOVIQ will also present initial results on the effectiveness of its TEXO-NET product for isolation of tumour-derived exosomes. This product combines the efficiency of INOVIQ's proprietary NETs technology with the cancer-specificity of our SubB2M technology.

INOVIQ CSO, Dr Greg Rice said: *"The abstracts being presented at ISEV support EXO-NET's broad utility in exosome isolation and biomarker discovery across multiple biofluids including plasma, serum, saliva and cell culture media. The new data reflects the significant achievements made by INOVIQ and its research collaborators over the past six months."*

The abstracts will be posted to INOVIQ's website at www.inoviq.com at the start of ISEV2023. The abstracts, authors and presenters are listed below:

1. Dynamic changes in the miRNA and protein content of circulating extracellular vesicles associated with ovarian cancer progression (#OT02.5)

Time: May 18, 2023 – 12.30pm-12.45pm
Authors: Dominic Guanzon, Andrew Lai, Carlos Palma, Ramin Khanabdali, Aase Handberg, Lewis Perrin, John Hooper, Jim Coward, Terry Morgan, Gregory E Rice, Carlos Salomon.
Presenter: Dominic Guanzon (UQ)

2. Reproducibility and efficiency of an extracellular vesicle capture technology for the detection of ovarian cancer (#PT01.02)

Time: May 18, 2023 – 4.45pm-6.45pm
Authors: Andrew Lai, Dominic Guanzon, Carlos Palma, Ramin Khanabdali, Lewis Perrin, John Hooper, Jim Coward, Gregory E Rice, Carlos Salomon
Presenter: Andrew Lai (UQ)

3. High-throughput isolation and enrichment of extracellular vesicles using an immunoaffinity magnetic bead-based matrix (# PF15.04)

Time: May 19, 2023 – 4.00pm-6.00pm
Authors: Ramin Khanabdali, Carlos Palma, Sara Nikseresht, Khairul Ansari, Susan Belzer, Laura F Dagley, Sukhdeep Spall, Huaqi Su, Laura Vella, Gregory Rice
Presenter: Ramin Khanabdali/Greg Rice (INOVIQ)

4. Tumor derived extracellular vesicles enrichment using a novel immunoaffinity magnetic bead-based matrix (#PF15.03)

May 19, 2023 – 4.00pm-6.00pm
Authors: Sara Nikseresht, Khairul Ansari, Ramin Khanabdali, Gregory Rice
Presenter: Ramin Khanabdali/Greg Rice (INOVIQ)

5. Enrichment of extracellular vesicles from human plasma with molecular net matrix-coated magnetic beads (EXO-NET®) (# PF10.10)

Time: May 19, 2023 – 4.00pm-6.00pm
Authors: Olesia Gololobova, Gregory E. Rice, Ramin Khanabdali, Kenneth W. Witwer
Presenter: Olesia Gololobova (JHU)

- ENDS -

Authorised by the Company Secretary, Mark Edwards.

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-Executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome isolation tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.